|
1
|
DeSantis CE, Ma J, Goding Sauer A, Newman
LA and Jemal A: Breast cancer statistics, 2017, racial disparity in
mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
3
|
Veronesi U, Boyle P, Goldhirsch A,
Orecchia R and Viale G: Breast cancer. Lancet. 365:1727–1741. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakamura S, Yagata H, Ohno S, Yamaguchi H,
Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K, et al:
Multi-center study evaluating circulating tumor cells as a
surrogate for response to treatment and overall survival in
metastatic breast cancer. Breast Cancer. 17:199–204. 2010.
View Article : Google Scholar
|
|
5
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weigelt B, Peterse JL and van ‘t Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cardoso F, Costa A, Senkus E, Aapro M,
André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso
MJ, et al: 3rd ESO-ESMO International Consensus Guidelines for
Advanced Breast Cancer (ABC 3). Ann Oncol. 28:16–33. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar :
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma XP, Zhang T, Peng B, Yu L and Jiang K:
Association between microRNA polymorphisms and cancer risk based on
the findings of 66 case-control studies. PLoS One. 8:e795842013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh T and Adams BD: The regulatory role
of miRNAs on VDR in breast cancer. Transcription. 8:232–241. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lü L, Mao X, Shi P, He B, Xu K, Zhang S
and Wang J: MicroRNAs in the prognosis of triple-negative breast
cancer: A systematic review and meta-analysis. Medicine
(Baltimore). 96:e70852017. View Article : Google Scholar
|
|
13
|
Evans-Knowell A, LaRue AC and Findlay VJ:
MicroRNAs and Their Impact on Breast Cancer, the Tumor
Microenvironment, and Disparities. Adv Cancer Res. 133:51–76. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao MQ, You AB, Zhu XD, Zhang W, Zhang YY,
Zhang SZ, Zhang KW, Cai H, Shi WK, Li XL, et al: miR-182-5p
promotes hepatocellular carcinoma progression by repressing FOXO3a.
J Hematol Oncol. 11:122018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu TB, Chen HS, Cao MQ, Guo FD, Cheng XY,
Han ZB and Li MQ: MicroRNA-421 inhibits caspase-10 expression and
promotes breast cancer progression. Neoplasma. 65:49–54. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lv ZD, Yang DX, Liu XP, Jin LY, Wang XG,
Yang ZC, Liu D, Zhao JJ, Kong B, Li FN, et al: MiR-212-5p
Suppresses the epithelial-mesenchymal transition in triple-negative
breast cancer by targeting Prrx2. Cell Physiol Biochem.
44:1785–1795. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He S, Wang G, Ni J, Zhuang J, Zhuang S,
Wang G, Ye Y and Xia W: MicroRNA-511 inhibits cellular
proliferation and invasion in colorectal cancer by directly
targeting hepatoma-derived growth factor. Oncol Res, 2018 Oncol
Res. Jan 10–2018.Epub ahead of print. View Article : Google Scholar
|
|
18
|
Fang Z, Zhang L, Liao Q, Wang Y, Yu F,
Feng M, Xiang X and Xiong J: Regulation of TRIM24 by miR-511
modulates cell proliferation in gastric cancer. J Exp Clin Cancer
Res. 36:172017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang C, Chi YL, Wang PY, Wang YQ, Zhang
YX, Deng J, Lv CJ and Xie SY: miR-511 and miR-1297 inhibit human
lung adenocarcinoma cell proliferation by targeting oncogene TRIB2.
PLoS One. 7:e460902012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang SQ, Yang Z, Cai XL, Zhao M, Sun MM,
Li J, Feng GX, Feng JY, Ye LH, Niu JQ, et al: miR-511 promotes the
proliferation of human hepatoma cells by targeting the 3′UTR of B
cell translocation gene 1 (BTG1) mRNA. Acta Pharmacol Sin.
38:1161–1170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de Anda-Jáuregui G, Espinal-Enríquez J,
Drago-García D and Hernández-Lemus E: Nonredundant, highly
connected MicroRNAs control functionality in breast cancer
networks. Int J Genomics. 2018:95853832018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chakravarty G, Moroz K, Makridakis NM,
Lloyd SA, Galvez SE, Canavello PR, Lacey MR, Agrawal K and Mondal
D: Prognostic significance of cytoplasmic SOX9 in invasive ductal
carcinoma and metastatic breast cancer. Exp Biol Med (Maywood).
236:145–155. 2011. View Article : Google Scholar
|
|
23
|
Riemenschnitter C, Teleki I, Tischler V,
Guo W and Varga Z: Stability and prognostic value of Slug, Sox9 and
Sox10 expression in breast cancers treated with neoadjuvant
chemotherapy. Springerplus. 2:6952013. View Article : Google Scholar
|
|
24
|
Müller P, Crofts JD, Newman BS,
Bridgewater LC, Lin CY, Gustafsson JA and Ström A: SOX9 mediates
the retinoic acid-induced HES-1 gene expression in human breast
cancer cells. Breast Cancer Res Treat. 120:317–326. 2010.
View Article : Google Scholar
|
|
25
|
Chakravarty G, Rider B and Mondal D:
Cytoplasmic compartmentalization of SOX9 abrogates the growth
arrest response of breast cancer cells that can be rescued by
trichostatin A treatment. Cancer Biol Ther. 11:71–83. 2011.
View Article : Google Scholar
|
|
26
|
Wang H, He L, Ma F, Regan MM, Balk SP,
Richardson AL and Yuan X: SOX9 regulates low density lipoprotein
receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4)
expression and Wnt/β-catenin activation in breast cancer. J Biol
Chem. 288:6478–6487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fazilaty H, Gardaneh M, Akbari P, Zekri A
and Behnam B: SLUG and SOX9 cooperatively regulate tumor initiating
niche factors in breast cancer. Cancer Microenviron. 9:71–74. 2016.
View Article : Google Scholar :
|
|
28
|
Jeselsohn R, Cornwell M, Pun M, Buchwalter
G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, et al:
Embryonic transcription factor SOX9 drives breast cancer endocrine
resistance. Proc Natl Acad Sci USA. 114:E4482–E4491. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
30
|
Liu Z, Yan Y, Cao S and Chen Y: Long
non-coding RNA SNHG14 contributes to gastric cancer development
through targeting miR-145/SOX9 axis. J Cell Biochem. 119:6905–6913.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xia S, Feng Z, Qi X, Yin Y, Jin J, Wu Y,
Wu H, Feng Y and Tao M: Clinical implication of Sox9 and activated
Akt expression in pancreatic ductal adenocarcinoma. Med Oncol.
32:3582015. View Article : Google Scholar
|
|
32
|
Drusco A and Croce CM: MicroRNAs and
cancer: A long story for short RNAs. Adv Cancer Res. 135:1–24.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kanwal R, Plaga AR, Liu X, Shukla GC and
Gupta S: MicroRNAs in prostate cancer: Functional role as
biomarkers. Cancer Lett. 407:9–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
O’Bryan S, Dong S, Mathis JM and Alahari
SK: The roles of oncogenic miRNAs and their therapeutic importance
in breast cancer. Eur J Cancer. 72:1–11. 2017. View Article : Google Scholar
|
|
35
|
Zheng Q, Cui X, Zhang D, Yang Y, Yan X,
Liu M, Niang B, Aziz F, Liu S, Yan Q, et al: miR-200b inhibits
proliferation and metastasis of breast cancer by targeting
fucosyltransferase IV and α1,3-fucosylated glycans. Oncogenesis.
6:e3582017. View Article : Google Scholar
|
|
36
|
Maimaitiming A, Wusiman A, Aimudula A,
Tudahong T and Aisimutula D: WITHDRAWN: Downregulation of
MicroRNA-152 and Inhibition of Cell Proliferation, Migration, and
Invasion in Breast Cancer. Oncol Res, Oncol Res. Jun 15–2017.Epub
ahead of print. View Article : Google Scholar : 032421
|
|
37
|
Wang J, Song C, Tang H, Zhang C, Tang J,
Li X, Chen B and Xie X: miR-629-3p may serve as a novel biomarker
and potential therapeutic target for lung metastases of
triple-negative breast cancer. Breast Cancer Res. 19:722017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sui Y, Zhang X, Yang H, Wei W and Wang M:
MicroRNA-133a acts as a tumour suppressor in breast cancer through
targeting LASP1. Oncol Rep. 39:473–482. 2018.
|
|
39
|
Degli Esposti D, Aushev VN, Lee E, Cros
MP, Zhu J, Herceg Z, Chen J and Hernandez-Vargas H: miR-500a-5p
regulates oxidative stress response genes in breast cancer and
predicts cancer survival. Sci Rep. 7:159662017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen X, Wang L, Qu J, Guan NN and Li JQ:
Predicting miRNA-disease association based on inductive matrix
completion. Bioinformatics. Jun 22–2018.Epub ahead of print.
View Article : Google Scholar
|
|
41
|
Chen X, Xie D, Wang L, Zhao Q, You ZH and
Liu H: BNPMDA: Bipartite Network Projection for MiRNA-disease
association prediction. Bioinformatics. 34:3178–3186. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen X and Huang L: LRSSLMDA: Laplacian
regularized sparse subspace learning for MiRNA-disease association
prediction. PLOS Comput Biol. 13:e10059122017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
You ZH, Huang ZA, Zhu Z, Yan GY, Li ZW,
Wen Z and Chen X: PBMDA: A novel and effective path-based
computational model for miRNA-disease association prediction. PLOS
Comput Biol. 13:e10054552017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen X, Xie D, Zhao Q and You ZH:
MicroRNAs and complex diseases: From experimental results to
computational models. Brief Bioinform. Oct 17–2017.Epub ahead of
print. View Article : Google Scholar
|
|
45
|
Chen X, Huang L, Xie D and Zhao Q:
EGBMMDA: Extreme gradient boosting machine for MiRNA-disease
association prediction. Cell Death Dis. 9:32018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang HH, Pang M, Dong W, Xin JX, Li YJ,
Zhang ZC, Yu L, Wang PY, Li BS and Xie SY: miR-511 induces the
apoptosis of radioresistant lung adenocarcinoma cells by triggering
BAX. Oncol Rep. 31:1473–1479. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang H, Leav I, Ibaragi S, Wegner M, Hu
GF, Lu ML, Balk SP and Yuan X: SOX9 is expressed in human fetal
prostate epithelium and enhances prostate cancer invasion. Cancer
Res. 68:1625–1630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhou CH, Ye LP, Ye SX, Li Y, Zhang XY, Xu
XY and Gong LY: Clinical significance of SOX9 in human non-small
cell lung cancer progression and overall patient survival. J Exp
Clin Cancer Res. 31:182012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bruun J, Kolberg M, Nesland JM, Svindland
A, Nesbakken A and Lothe RA: Prognostic significance of β-catenin,
E-cadherin, and SOX9 in colorectal cancer: Results from a large
population-representative series. Front Oncol. 4:1182014.
View Article : Google Scholar
|
